Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023

Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall

VLO : 162.86 (-0.56%)
ADBE : 478.35 (-1.31%)
MIRM : 25.51 (+0.83%)
DOOR : 132.84 (+0.05%)
NIO : 5.21 (-0.19%)
ILMN : 107.79 (-0.68%)
Why Shares of Travere Therapeutics Are Slumping Thursday

A mixed trial could hurt a kidney drug's chances of full approval.

MIRM : 25.51 (+0.83%)
TVTX : 6.45 (+4.54%)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MIRM : 25.51 (+0.83%)
YMAB : 12.06 (+2.03%)
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

MIRM : 25.51 (+0.83%)
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ADPT : 3.50 (-2.51%)
MIRM : 25.51 (+0.83%)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 0.6350 (-0.56%)
MIRM : 25.51 (+0.83%)
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...

MIRM : 25.51 (+0.83%)
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?

IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

IDYA : 41.57 (+3.10%)
MIRM : 25.51 (+0.83%)
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...

MIRM : 25.51 (+0.83%)
American Airlines, Emerson Electric fall; Triton, Chart rise

Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise

MIRM : 25.51 (+0.83%)
TRTN : 79.55 (-4.10%)
EMR : 113.87 (+0.15%)
TH.TO : 1.80 (+1.69%)
NATI : 59.98 (unch)
NCMI : 4.95 (+0.81%)
GTLS : 156.42 (+0.26%)

Barchart Exclusives

Investing in Gold? Forget GLD, Buy PHYS Instead
Many groups are piling into gold, including central banks and sovereign governments. Gold has also become very popular among individual Chinese investors and family offices that cater to the global rich. Most of these investors choose physical gold. That's what famed investor Michael Burry did. But instead of the GLD ETF, he opted for another physical gold ETF - PHYS. Find out why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar